Literature DB >> 8444223

Intellectual performance of children with maple syrup urine disease.

C Hilliges1, D Awiszus, U Wendel.   

Abstract

The intellectual performance of 22 children aged 3-16 years with maple syrup urine disease (MSUD) was assessed and compared to a group of early treated phenylketonuria (PKU) children and normal subjects matched by age, sex, nationality, and socio-economic status. All subjects were tested by one examiner only using the age related versions of the non-verbal Snijders-Oomen intelligence test. The mean IQ (+/- SD) score was 74 +/- 14 (range 50-103) in patients with MSUD, 101 +/- 12 (range 87-125) in early treated PKU patients, and 107 +/- 9 (range 90-122) in normal subjects. Intercorrelations indicated that length of time after birth that plasma leucine concentration remained > 1 mmol/l and quality of long-term metabolic control have important influences on IQ.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444223     DOI: 10.1007/bf02072492

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in patients with maple syrup urine disease.

Authors:  G T Berry; R Heidenreich; P Kaplan; F Levine; A Mazur; M J Palmieri; M Yudkoff; S Segal
Journal:  N Engl J Med       Date:  1991-01-17       Impact factor: 91.245

2.  Treatment outcome of maple syrup urine disease.

Authors:  S E Snyderman
Journal:  Acta Paediatr Jpn       Date:  1988-08

3.  Management of maple syrup urine disease in Canada. Committee for improvement of Hereditary Disease Management.

Authors: 
Journal:  Can Med Assoc J       Date:  1976-11-20       Impact factor: 8.262

4.  Intellectual outcome in children with maple syrup urine disease.

Authors:  P Kaplan; A Mazur; M Field; J A Berlin; G T Berry; R Heidenreich; M Yudkoff; S Segal
Journal:  J Pediatr       Date:  1991-07       Impact factor: 4.406

5.  Results of psychological testing of patients aged 3-6 years.

Authors:  U Michel; E Schmidt; U Batzler
Journal:  Eur J Pediatr       Date:  1990       Impact factor: 3.183

6.  Correlations between branched-chain amino acids and branched-chain alpha-keto acids in blood in maple syrup urine disease.

Authors:  U Langenbeck; U Wendel; A Mench-Hoinowski; D Kuschel; K Becker; H Przyrembel; H J Bremer
Journal:  Clin Chim Acta       Date:  1978-09-01       Impact factor: 3.786

7.  The relationship between the branched chain amino acids and their alpha-ketoacids in maple syrup urine disease.

Authors:  S E Snyderman; F Goldstein; C Sansaricq; P M Norton
Journal:  Pediatr Res       Date:  1984-09       Impact factor: 3.756

8.  Outcome of early and long-term management of classical maple syrup urine disease.

Authors:  C L Clow; T M Reade; C R Scriver
Journal:  Pediatrics       Date:  1981-12       Impact factor: 7.124

9.  Outcome of maple syrup urine disease.

Authors:  E R Naughten; J Jenkins; D E Francis; J V Leonard
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

  9 in total
  19 in total

1.  Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience.

Authors:  George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

2.  The longest-surviving patient with classical maple syrup urine disease.

Authors:  Carel le Roux; Elaine Murphy; Maggie Lilburn; Philip J Lee
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

3.  Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease.

Authors:  E Simon; R Fingerhut; J Baumkötter; V Konstantopoulou; R Ratschmann; U Wendel
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

4.  Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism.

Authors:  I-Jung Tsai; Wuh-Liang Hwu; Shu-Chien Huang; Ni-Chung Lee; En-Ting Wu; Yin-Hsiu Chien; Yong-Kwei Tsau
Journal:  Pediatr Nephrol       Date:  2013-09-08       Impact factor: 3.714

Review 5.  Maple syrup urine disease 1954 to 1993.

Authors:  F Peinemann; D J Danner
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 6.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

Review 7.  Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.

Authors:  Jean-Baptiste Arnoux; Kim-Hanh Le Quan Sang; Anais Brassier; Coraline Grisel; Aude Servais; Julien Wippf; Sandrine Dubois; Nicolas Sireau; Chantal Job-Deslandre; Lakshminarayan Ranganath; Pascale de Lonlay
Journal:  J Inherit Metab Dis       Date:  2015-04-10       Impact factor: 4.982

Review 8.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 9.  Animal models of maple syrup urine disease.

Authors:  K J Skvorak
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

10.  Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model.

Authors:  Véronique Phan; Marie-José Clermont; Aicha Merouani; Catherine Litalien; Marisa Tucci; Marie Lambert; Grant Mitchell; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.